Table 3

Subgroup analyses of the incidence of diabetic retinopathy by intervention group in the PREDIMED trial after a median 6.1 years of follow-up

Events/totalHR (95% CI)P for interaction
MedDiet+EVOOMedDiet+NutsControl groupMedDiet+EVOOMedDiet+NutsEVOOEVOO+Nuts
Sex
 Male9/57410/5938/5400.76 (0.28–2.04)0.82 (0.31–2.16)0.380.33
 Female13/70810/54924/6500.46 (0.23–0.92)0.51 (0.24–1.08)
Age, years*
 <7018/79014/72917/7090.84 (0.42–1.66)0.74 (0.36–1.54)0.20*0.38*
 ≥704/4926/41315/4810.24 (0.07–0.73)0.47 (0.17–1.26)
BMI, kg/m2
 <3015/68911/63012/6081.00 (0.46–2.18)0.80 (0.34–1.86)0.59*0.74*
 ≥307/5969/51220/5820.26 (0.10–0.62)0.50 (0.23–1.12)
Hypertension
 No7/3085/29214/2680.35 (0.14–0.89)0.31 (0.10–0.90)0.620.28
 Yes15/97415/85018/9220.70 (0.34–1.42)0.90 (0.45–1.82)
Dyslipidemia
 No13/51814/46918/4850.60 (0.28–1.23)0.78 (0.38–1.62)0.860.47
 Yes9/7646/67314/7050.50 (0.20–1.17)0.41 (0.16–1.10)
MedDiet adherence at baseline (0 to 14 score)
 <1011/84115/73524/8780.47 (0.23–0.97)0.75 (0.38–1.48)0.100.18
 ≥1011/4415/4078/3120.68 (0.26–1.79)0.31 (0.09–1.09)
  • All models are fully adjusted for the confounders shown in model 1 in Table 2 and stratified by center.

  • †Two interactions were assessed: only for the effect of MedDiet+EVOO (1 degree of freedom) and for both groups (2 degrees of freedom).

  • *The interactions with age and BMI were assessed using age and BMI as continuous variables.